Relmada Therapeutics, Inc. RLMD EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s EPS (diluted)?
- Relmada Therapeutics, Inc. (RLMD) reported EPS (diluted) of -$0.22 in Q1 2026.
- How has Relmada Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Relmada Therapeutics, Inc.'s EPS (diluted) increased by 62.1% year-over-year, from -$0.58 to -$0.22.
- What is the long-term trend for Relmada Therapeutics, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s EPS (diluted) has grown at a -32.6% compound annual growth rate (CAGR), from -$7.14 to -$1.47.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.